“…Currently, based on the novel enterovirus isolates available in GenBank database, most novel enterovirus genotypes except for EV-D68 and EV-A71 have been isolated in the mainland of China, and the clinical manifestation of the vast majority of cases related to novel enterovirus is AFP ( Oberste et al, 2004 ; Bingjun et al, 2008 ; Tao et al, 2010 , 2013 , 2014a ; Xu et al, 2011a , b ; Sun et al, 2013 ; Hu et al, 2014 ; Liu et al, 2014 ; Lu et al, 2014 ; Tang et al, 2014 ; Zhang et al, 2014 , 2016 ; Fan et al, 2015 ; Song et al, 2017 ; Han et al, 2018 ; Huang et al, 2018 ; Wang et al, 2019 ). A considerable number of strains have been isolated from healthy people ( Wu et al, 2013 ; Hu et al, 2014 ; Tao et al, 2014b ; Fan et al, 2015 ; Tang et al, 2016 ; Zhang et al, 2016 ; Song et al, 2017 ; Han et al, 2018 ; Zhang et al, 2019 ), directly indicating that the population carries the novel enteroviruses and is at risk of developing the related diseases. Of these, a large number of cases arising from some novel enterovirus serotypes have already been reported in China, such as EV-B85 in Xinjiang ( Sun et al, 2013 ) (33 cases, 2011, AFP and his asymptomatic contacts), EV-A90 in Xinjiang ( Huang et al, 2018 ) (5 cases, 2011, AFP) and Shandong ( Tao et al, 2013 ) (3 cases, 2001, AFP), EV-C96 in Yunnan ( Bingjun et al, 2008 ) (18 cases, 1999-2010, AFP), and Jiangxi Province (13 cases, 2016, unknown), and EV-C104 in Shandong ( Xiang et al, 2013 ) (five cases, 2011–2012, lower respiratory tract infection).…”